Vera Therapeutics’ TRUTAKNA™ Achieves Significant Results in ORIGIN 3 Final Efficacy Analysis
Thursday, 22 October 2026, 14:05
Key Findings from the ORIGIN 3 Analysis
In the recent ORIGIN 3 final efficacy analysis, TRUTAKNA™ (atacicept-vymj) by Vera Therapeutics achieved remarkable results in addressing IgA nephropathy. The study demonstrated statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope.
Significant Endpoint Achievements
- Statistical significance in eGFR change
- Annualized slope improvements
- Risk reduction in renal outcomes
The presentation during ASN Kidney Week 2026 has highlighted TRUTAKNA™'s potential to transform treatment landscapes in nephrology, as detailed in the New England Journal of...
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.